TEVATEVA PHARMACEUTICAL INDUSTR...

NYSE tevapharm.com


$ 16.48 $ 0.14 (0.86 %)    

Tuesday, 02-Jul-2024 12:28:13 EDT
QQQ $ 483.19 $ 3.30 (0.69 %)
DIA $ 391.16 $ 0.32 (0.08 %)
SPY $ 545.90 $ 2.16 (0.4 %)
TLT $ 90.16 $ 0.25 (0.28 %)
GLD $ 214.82 $ -0.75 (-0.35 %)
$ 16.34
$ 16.24
$ 16.48 x 600
$ 16.52 x 100
$ 16.10 - $ 16.50
$ 7.42 - $ 17.69
18,722,248
na
18.51B
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-12-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-12-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ftc-crackdown-on-teva-pharmaceuticals-over-inhaler-patent-abuse

The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain h...

Core News & Articles

https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/The Federal Trade Commission has opened an ...

 teva-pharmaceuticals-presents-4th-interim-analysis-of-pearl-migraine-prevention-study-at-ean-congress-new-sub-analysis-highlights-potential-negative-impact-of-treatment-pauses-on-patient-outcomes

4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) co...

 jefferies-maintains-buy-on-teva-pharmaceutical-indus-raises-price-target-to-23

Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target fro...

 teva-enters-agreement-with-israel-tax-authority-resolving-all-pending-litigation-agrees-to-pay-total-of-750m-in-installments-between-2024-to-2029

This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients ...

 teva-pharmaceutical-industries-launches-authorized-generic-of-victoza-in-united-states

Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. marke...

 teva-engages-in-settlement-talks-over-medicare-kickback-allegations

Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copax...

 concerpt-therapeutics-shares-are-trading-lower-what-you-need-to-know

Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceu...

Core News & Articles

Teva sues Corcept over mifepristone 'monopoly' for rare disorder | Reuters

Core News & Articles

https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...

 barclays-maintains-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-21

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

 teva-announced-saturday-switching-to-uzedy-at-four-weeks-after-the-last-dose-of-once-monthly-paliperidone-palmitate-provided-the-most-comparable-pharmacokinetic-profile-based-on-the-relevant-pk-modeling-data-for-schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the present...

 b-of-a-securities-maintains-buy-on-teva-pharmaceutical-indus-raises-price-target-to-21

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price tar...

 reported-earlier-tevas-austedo-xr-receives-fda-green-light-one-pill-once-daily-dosage-now-available-for-td-and-hd-chorea

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility wit...